Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development

Viruses. 2024 Jan 16;16(1):128. doi: 10.3390/v16010128.

Abstract

SFTSV is an emerging tick-borne virus causing hemorrhagic fever with a case fatality rate (CFR) that can reach up to 27%. With endemic infection in East Asia and the recent spread of the vector tick to more than 20 states in the United States, the SFTSV outbreak is a globally growing public health concern. However, there is currently no targeted antiviral therapy or licensed vaccine against SFTSV. Considering the age-dependent SFTS pathogenesis and disease outcome, a sophisticated vaccine development approach is required to safeguard the elderly population from lethal SFTSV infection. Given the recent emergence of SFTSV, the establishment of animal models to study immunogenicity and protection from SFTS symptoms has only occurred recently. The latest research efforts have applied diverse vaccine development approaches-including live-attenuated vaccine, DNA vaccine, whole inactivated virus vaccine, viral vector vaccine, protein subunit vaccine, and mRNA vaccine-in the quest to develop a safe and effective vaccine against SFTSV. This review aims to outline the current progress in SFTSV vaccine development and suggest future directions to enhance the safety and efficacy of these vaccines, ensuring their suitability for clinical application.

Keywords: SFTSV; emerging virus; tick-borne disease; vaccine.

Publication types

  • Review

MeSH terms

  • Aged
  • Animals
  • Disease Outbreaks
  • Humans
  • Models, Animal
  • Severe Fever with Thrombocytopenia Syndrome*
  • Vaccine Development
  • Vaccines, Attenuated
  • Viral Vaccines*

Substances

  • Vaccines, Attenuated
  • Viral Vaccines